Overview

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

Status:
Terminated

Trial end date:
2007-10-01

Target enrollment:

Participant gender:

Summary

To identify the proportion of patients remaining medically castrated (testosterone level < 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.

Phase:

Phase 3

Details

Lead Sponsor:

Ipsen

Treatments:

Triptorelin Pamoate